Potential new treatment for rhabdoid brain tumors
Researchers at the Princess Máxima Center have found a promising potential treatment for ATRT brain tumors in children using the existing cancer drug gemcitabine.
Potential new treatment for atypical teratoid rhabdoid tumors in the brain
Researchers at the Princess Máxima Center have discovered a potential new treatment for atypical teratoid rhabdoid tumors (ATRT) in the brain. Lab studies using new research models show promising results: the drug gemcitabine kills tumor cells. Dr. Dennis Metselaar says: “Gemcitabine is already an approved drug for other types of cancer. Preparations for a potential clinical study have begun.”
In the Netherlands, around three children are diagnosed with an ATRT each year. These tumors usually occur in the brain. Currently, only a small number of children are cured through surgery, intensive chemotherapy, and high-dose radiation. Research into better treatments is therefore crucial to increase survival rates.
Tumor cell death
Dr. Dennis Metselaar, postdoctoral researcher in the Hulleman Group, and his colleagues studied the effect of gemcitabine on ATRT cells in the lab. This followed screening of more than 140 drugs on various types of pediatric brain tumors. The results showed that ATRT, unlike other brain tumor types, is highly sensitive to gemcitabine. The sonic hedgehog (SHH) variant, which is both the most common and most aggressive form, was especially sensitive.
The team developed new models for this research, including mouse models and tumor cell cultures, using tumor cells from a child previously treated for ATRT. Large-scale testing on cell cultures showed gemcitabine to be the most effective drug for ATRT. They then validated its effects on full tumors in mice. After treatment, the mice lived over 30% longer on average compared to those treated with existing therapies. Remarkably, two treated mice survived the entire study period.
Metselaar: “This research is still in an early phase, but the results are encouraging. It’s the first time we’ve seen mice with ATRT live significantly longer from a single drug with minimal side effects.”
The results of the study were published today in Cell Reports Medicine. The Hulleman Group has also made its new research models—cell cultures and mouse models—available to other researchers. The research was funded by KiKa (Children Cancer-free Foundation).
On a molecular level
To understand how the drug works, Metselaar and his colleagues examined ATRT cells at the molecular level. “We observed that gemcitabine reduces the SIRT1 protein in the cell. As a result, two other proteins—NF-kB and p53—increase. Unlike in many other (brain) tumors, these proteins are not commonly mutated in ATRT, but merely suppressed. They then trigger tumor cell death. Due to this direct link with SIRT1, and the specific effect of gemcitabine on this protein, we believe this explains why the drug is so effective.”
Next steps
Lab research shows that ATRT is highly sensitive to treatment with gemcitabine.
Dr. Esther Hulleman, group leader and principal investigator: “These results indicate that this drug could potentially become part of ATRT treatment—possibly in combination with other drugs. The next step is translating this to a clinical study. Since gemcitabine is already approved for use in childhood cancer, this process could move more quickly. A clinical trial will help determine whether our lab findings can indeed help more children with this aggressive cancer survive.”
Source: Princess Máxima Center
Living Lab in the Spotlight: Utrecht Science Park
Utrecht Science Park is home to several living labs focused on energy and circularity. These include Lumifield, which explores the generation and storage of solar energy, and the biogas digester, which uses organic waste as an energy source. On their own, these are already promising initiatives. Connected, they could become something much bigger: a functioning, learning model for a circular campus.
From student idea during challenge to ReGreen Hut at Dutch Design Week
On hot summer days, temperatures can rise significantly at Utrecht Science Park, while students are looking for places to study, relax and find some shade outdoors. At the same time, planting trees is not always straightforward: underground, the campus is crisscrossed by a dense network of cables and utility lines. So how can we create shade, greenery and places to relax without major changes to the ground?
Utrecht Science Week kicks off: social and economic impact of Utrecht Science Park in the spotlight
The sixth edition of Utrecht Science Week takes place from Friday, 25 September to Sunday, 4 October. During this time, Utrecht Science Park opens its doors to the general public, showcasing how research, innovation, and collaboration lead to tangible societal and economic impact. At the same time, the week underscores the importance of sustained investment in knowledge and innovation.
Looking back at Utrecht Science Week: research, education, and entrepreneurship in the spotlight
Utrecht Science Week 2026 has come to a close. For over a week, visitors enjoyed workshops, lectures, group discussions, and tours focused on science and innovation at Utrecht Science Park. With more than thirty program activities across over 25 locations, there were ample opportunities to experience science up close. We look back on a fantastic week that once again highlighted the essential role of collaboration, and the combination of research, education, and entrepreneurship, in addressing the societal challenges of our time.